Morgan Stanley Adjusts Integral Diagnostics' Price Target to AU$1.85 From AU$1.70, Keeps at Underweight
Analysts Offer Insights on Healthcare Companies: Integral Diagnostics Ltd. (AU:IDX), Biophytis SA (Stuttgart: DE:6XB) and Merck KGaA (GB:0O14)
No Data